http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 16 Oct 2026 10:51:45 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Oct+08/27163230.html si-local-file:///var/storage/secattach/20261008/27163230.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Oct+08/27163230.html Thu, 08 Oct 2026 06:28:00 -0400 CATX http://www.streetinsider.com/Corporate+News/FDA+grants+fast+track+designation+to+Perspective+Therapeutics%27+PSV359/27163191.html <p>Perspective Therapeutics, Inc. (NYSE American: CATX) announced that the U.S. Food and Drug Administration granted Fast Track Designation for PSV359, an investigational radiopharmaceutical therapy targeting adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors (SFTs).</p><p>SFT is a rare cancer with limited treatment options for patients with locally advanced unresectable or metastatic disease. PSV359, designated [²¹²Pb]PSV359, is a FAP-targeted alpha-particle therapy currently being evaluated in an ongoing Phase 1/2a clinical study in patients with advanced FAP-positive solid tumors.</p><p>The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies for http://www.streetinsider.com/Corporate+News/FDA+grants+fast+track+designation+to+Perspective+Therapeutics%27+PSV359/27163191.html Thu, 08 Oct 2026 06:16:45 -0400 CATX http://www.streetinsider.com/FDA/FDA+grants+fast+track+designation+to+Perspective+Therapeutics%27+PSV359/27163191.html <p>Perspective Therapeutics, Inc. (NYSE American: CATX) announced that the U.S. Food and Drug Administration granted Fast Track Designation for PSV359, an investigational radiopharmaceutical therapy targeting adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors (SFTs).</p><p>SFT is a rare cancer with limited treatment options for patients with locally advanced unresectable or metastatic disease. PSV359, designated [²¹²Pb]PSV359, is a FAP-targeted alpha-particle therapy currently being evaluated in an ongoing Phase 1/2a clinical study in patients with advanced FAP-positive solid tumors.</p><p>The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies for http://www.streetinsider.com/FDA/FDA+grants+fast+track+designation+to+Perspective+Therapeutics%27+PSV359/27163191.html Thu, 08 Oct 2026 06:16:45 -0400 CATX http://www.streetinsider.com/Hot+Corp.+News/FDA+grants+fast+track+designation+to+Perspective+Therapeutics%27+PSV359/27163191.html <p>Perspective Therapeutics, Inc. (NYSE American: CATX) announced that the U.S. Food and Drug Administration granted Fast Track Designation for PSV359, an investigational radiopharmaceutical therapy targeting adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors (SFTs).</p><p>SFT is a rare cancer with limited treatment options for patients with locally advanced unresectable or metastatic disease. PSV359, designated [²¹²Pb]PSV359, is a FAP-targeted alpha-particle therapy currently being evaluated in an ongoing Phase 1/2a clinical study in patients with advanced FAP-positive solid tumors.</p><p>The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies for http://www.streetinsider.com/Hot+Corp.+News/FDA+grants+fast+track+designation+to+Perspective+Therapeutics%27+PSV359/27163191.html Thu, 08 Oct 2026 06:16:45 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Oct+01/27135985.html si-local-file:///var/storage/secattach/20261001/27135985.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Oct+01/27135985.html Thu, 01 Oct 2026 16:08:00 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Perspective+Therapeutics+++++++++++++++Filed+by%3A+Lantheus+Holdings%2C+Inc./27096941.html si-local-file:///var/storage/secattach/20260923/27096941.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Perspective+Therapeutics+++++++++++++++Filed+by%3A+Lantheus+Holdings%2C+Inc./27096941.html Wed, 23 Sep 2026 16:20:00 -0400 CATX http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Perspective+Therapeutics+Inc+%28CATX%29+at+Outperform/27077844.html <p>William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics Inc (NYSE: CATX) with a Outperform rating.</p><p>The analyst comments "In our view, Perspective is well positioned to leverage lead-212-based radiopharmaceuticals with its peptide platform and established supply chain. We believe lead-212 is an intriguing alpha-emitting radioisotope given its ability to cause double-stranded DNA breaks, its short half-life, and its single decay nature. Perspective’s peptides are engineered to exhibit high tumor specificity and rapid blood clearance, while the chelator is designed to retain the daughter isotope and be rapidly cleared through the kidneys. Taken together, we believe these characteristics of Perspective’s http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Perspective+Therapeutics+Inc+%28CATX%29+at+Outperform/27077844.html Fri, 18 Sep 2026 06:05:13 -0400 CATX http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Perspective+Therapeutics+Inc+%28CATX%29+at+Outperform/27077844.html <p>William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics Inc (NYSE: CATX) with a Outperform rating.</p><p>The analyst comments "In our view, Perspective is well positioned to leverage lead-212-based radiopharmaceuticals with its peptide platform and established supply chain. We believe lead-212 is an intriguing alpha-emitting radioisotope given its ability to cause double-stranded DNA breaks, its short half-life, and its single decay nature. Perspective’s peptides are engineered to exhibit high tumor specificity and rapid blood clearance, while the chelator is designed to retain the daughter isotope and be rapidly cleared through the kidneys. Taken together, we believe these characteristics of Perspective’s http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Perspective+Therapeutics+Inc+%28CATX%29+at+Outperform/27077844.html Fri, 18 Sep 2026 06:05:13 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Sep+14/27055000.html si-local-file:///var/storage/secattach/20260914/27055000.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Sep+14/27055000.html Mon, 14 Sep 2026 06:20:00 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Sep+08/27037562.html si-local-file:///var/storage/secattach/20260908/27037562.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Sep+08/27037562.html Tue, 08 Sep 2026 17:17:00 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Perspective+Therapeutics++For%3A+Sep+03++Filed+by%3A+Lantheus+Holdings%2C+Inc./27037348.html si-local-file:///var/storage/secattach/20260908/27037348.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Perspective+Therapeutics++For%3A+Sep+03++Filed+by%3A+Lantheus+Holdings%2C+Inc./27037348.html Tue, 08 Sep 2026 16:51:00 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Perspective+Therapeutics++For%3A+Sep+02++Filed+by%3A+Lantheus+Holdings%2C+Inc./27030559.html si-local-file:///var/storage/secattach/20260904/27030559.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Perspective+Therapeutics++For%3A+Sep+02++Filed+by%3A+Lantheus+Holdings%2C+Inc./27030559.html Fri, 04 Sep 2026 17:01:00 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Perspective+Therapeutics++For%3A+Aug+31++Filed+by%3A+Lantheus+Alpha+Therapy%2C+LLC/27030514.html si-local-file:///var/storage/secattach/20260904/27030514.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Perspective+Therapeutics++For%3A+Aug+31++Filed+by%3A+Lantheus+Alpha+Therapy%2C+LLC/27030514.html Fri, 04 Sep 2026 16:59:00 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Perspective+Therapeutics+++++++++++++++Filed+by%3A+Lantheus+Holdings%2C+Inc./27030455.html si-local-file:///var/storage/secattach/20260904/27030455.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Perspective+Therapeutics+++++++++++++++Filed+by%3A+Lantheus+Holdings%2C+Inc./27030455.html Fri, 04 Sep 2026 16:49:00 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Perspective+Therapeutics++For%3A+Sep+01++Filed+by%3A+Lantheus+Holdings%2C+Inc./27025812.html si-local-file:///var/storage/secattach/20260903/27025812.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Perspective+Therapeutics++For%3A+Sep+01++Filed+by%3A+Lantheus+Holdings%2C+Inc./27025812.html Thu, 03 Sep 2026 16:54:00 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Perspective+Therapeutics++For%3A+Aug+31++Filed+by%3A+Lantheus+Holdings%2C+Inc./27019697.html si-local-file:///var/storage/secattach/20260902/27019697.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Perspective+Therapeutics++For%3A+Aug+31++Filed+by%3A+Lantheus+Holdings%2C+Inc./27019697.html Wed, 02 Sep 2026 16:36:00 -0400 CATX http://www.streetinsider.com/New+Coverage/BMO+Capital+Starts+Perspective+Therapeutics+Inc+%28CATX%29+at+Outperform/26944365.html (Updated - August 19, 2026 5:33 AM EDT) <p>BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics Inc (NYSE: CATX) with a Outperform rating, PT $11.00.</p><p>The analyst comments "We initiate coverage of Perspective Therapeutics with an Outperform rating and an $11 target price. Perspective is developing differentiated precision radioligand therapies using its proprietary lead-212 platform and paired imaging agents. Led by bamzireotide navoxetan in neuroendocrine tumors, its pipeline combines encouraging clinical efficacy & safety with opportunities across melanoma and FAP-expressing solid tumors. Assets could support meaningful differentiation from competitors. Supported by promising clinical, preclinical, and initial human imaging data, we http://www.streetinsider.com/New+Coverage/BMO+Capital+Starts+Perspective+Therapeutics+Inc+%28CATX%29+at+Outperform/26944365.html Wed, 19 Aug 2026 05:33:30 -0400 CATX